Galapagos NV

Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer

02 May 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

26 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting

25 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos and NovAliX enter into an integrated drug discovery collaboration

30 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting

23 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

20 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

27 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces full year 2022 results and outlook for 2023

23 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

09 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

08 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

10 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

03 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

23 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces changes to Executive Committee

22 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

13 Dec 2022 00:00:00 By Nasdaq GlobeNewswire

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

11 Nov 2022 06:15:00 By Nasdaq GlobeNewswire

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

08 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

04 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

03 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos to host its R&D Update 2022 in New York on 4 November 2022

17 Oct 2022 00:30:00 By Nasdaq GlobeNewswire